ストックスクリーナーアプリを入手
11.80
0.76%
-0.09
アフターアワーズ：
11.80
前日終値:
$11.89
開ける：
$11.82
24時間の取引高:
702.86K
Relative Volume:
1.20
時価総額：
$586.70M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-3.1978
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
+2.88%
1か月 パフォーマンス:
-9.79%
6か月 パフォーマンス:
+17.30%
1年 パフォーマンス:
+4.89%
1日の値動き範囲:
$11.44
$11.87
1週間の範囲:
$11.11
$11.93
52週間の値動き範囲:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.80 | 570.24M | 0 | -156.39M | -123.06M | -3.69 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KalVista Pharmaceuticals to Present at the Jefferies Global Heal - GuruFocus
KalVista Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Jane Street Group LLC - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Position Lessened by D. E. Shaw & Co. Inc. - Defense World
Northern Trust Corp Sells 13,205 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
(KALV) Proactive Strategies - news.stocktradersdaily.com
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings - Business Wire
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
(KALV) Investment Analysis - news.stocktradersdaily.com
Tower Research Capital LLC TRC Has $54,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Dimensional Fund Advisors LP Acquires 89,001 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Head-To-Head Comparison: KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of “Buy” by Analysts - Defense World
Wells Fargo & Company MN Has $171,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
MetLife Investment Management LLC Lowers Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 11 - marketscreener.com
Analyzing Ratios: KalVista Pharmaceuticals Inc (KALV)’s Financial Story Unveiled - DWinneX
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
JPMorgan Chase & Co. Decreases Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Trading (KALV) With Integrated Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 - BioSpace
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Should investors be concerned about KalVista Pharmaceuticals Inc (KALV)? - uspostnews.com
KalVista Pharmaceuticals Inc [KALV] Shares Jump Approximately 27.74% Over the Year - knoxdaily.com
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference - BioSpace
KalVista Pharmaceuticals Inc (KALV) stock analysis: A comprehensive overview - uspostnews.com
Geode Capital Management LLC Sells 8,632 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Kalvista stock holds $19 target, Market Outperform rating - Investing.com
Kalvista stock holds $19 target, Market Outperform rating By Investing.com - Investing.com India
Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com
(KALV) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle
The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter
KalVista: Poised For Rare Disease Transformation - Seeking Alpha
Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News
KalVista licensing deal with Kaken - The Pharma Letter
KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia
KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa
KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):